Urinary protein products
Human urine contains a variety of trace active ingredients that have therapeutic effects on diseases. Aidea Pharma uses urine as a source to extract and purify a series of urinary protein products, mainly including crude product/intermediate of Ulinastatin, Urinary Kallidinogenase and Urokinase. And supply to downstream formulation enterprises for the manufacture of drug substances for the corresponding formulations.
-
Core competitiveness
The traditional urinary protein production process requires the collection of urine and multiple acid-base adjustments. The process is cumbersome with great difficulty in collection, which easily causes pollution to the environment. In the process of urbanization, the increased labor cost, the environment and hygiene requirement make such process more and more restricted. Aidea Pharma has developed the fresh flow adsorption technology to overcome the obstacle. This environment-friendly process can efficiently adsorb urinary protein that flowing through resin, and realize the collection of urinary proteins in big cities. Ensured with patents and technical know-how, Aidea Pharma has built strong technical and resource barriers as core competitiveness.
-
Innovative drug research and development
On the basis of core technology and dominant position, Aidea Pharma actively extends the industrial chain of urinary protein, and is exploring downstream pipelines of urinary protein products for anti-inflammation and cerebral stroke.
Industrial chain of urinary protein
